Article Details

Pricey new gene therapies for sickle cell pose access test | BioPharma Dive

Retrieved on: 2023-12-08 23:10:43

Tags for this article:

Click the tags to see associated articles and topics

Pricey new gene therapies for sickle cell pose access test | BioPharma Dive. View article details on hiswai:

Excerpt

Casgevy, the first CRISPR therapy approved by the FDA, will cost $2.2 million, while a competing genetic medicine also cleared Friday is priced at ...

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo